Owen Smith

Owen Smith has a diverse work experience in the biotech and life sciences industries. Owen started their career at Grant Thornton UK LLP, where they held roles as an Associate and later as an Executive from September 2010 to April 2015. In February 2015, they joined Arthurian Life Sciences as a Life Sciences VC, and then moved to Arix Bioscience plc in February 2016, also as a Life Sciences VC.

In March 2016, Owen became a Board Observer at Depixus, a position they held until December 2017. During this time, they also served as a Board Observer at LogicBio Therapeutics from May 2017 to December 2017. LogicBio is a gene-therapy company focused on developing cures for early-onset life-threatening diseases.

In 2019, Owen joined Entact Bio as a Director, and in 2020, they took on a Director role at SparingVision, a biotechnology company specializing in the discovery and development of therapies for inherited retinal diseases.

Currently, Owen is a Partner at 4BIO Capital since January 2022. Prior to this, they held positions at 4BIO Capital as an Investment Director from August 2019 to March 2022, and as a Principal from January 2018 to August 2019. At 4BIO Capital, Owen focused on investments in public and private advanced therapies companies, with a specialization in biotech investments.

Owen Smith's education history begins in 2005 when they attended the University of Bristol and earned a Bachelor of Science (BSC) degree in Biological Sciences, which they completed in 2008. After a brief hiatus, they pursued further education at CIPFA from 2010 to 2013, where they obtained a CPFA degree. In 2017, Owen Smith enrolled at the University of Oxford and completed a Master of Science (MS) degree in Experimental and Translational Therapeutics in 2020.